| Business Summary | | Trinity
Biotech
plc
develops,
manufactures
and
markets
rapid
diagnostic
test
kits
used
for
the
clinical
laboratory,
point-of-care
(POC)
and
self-testing
(OTC)
segments
of
the
diagnostic
market.
The
Company's
rapid
tests
provide
fast
and
accurate
results
designed
for
home
(OTC)
and
doctor's
office
(POC)
use.
In
addition,
the
Company
manufactures
and
markets
a
range
of
diagnostic
test
kits
used
in
clinical
laboratories
to
detect
infectious
diseases
and
autoimmune
disorders.
The
Company
markets
over
120
different
diagnostic
products
in
over
75
countries. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Trinity
Biotech
plc
develops,
manufactures,
and
markets
rapid
diagnostic
test
kits
used
for
the
clinical
laboratory,
point
of
care
and
self
testing
segments
of
the
diagnostic
market.
For
three
months
ended
3/01,
revenues
rose
21%
to
$8.3
million.
Net
income
before
U.
S.
GAAP
fell
30%
to
$984
thousand.
Revenues
reflect
acquisitions
and
launches
of
new
products.
Earnings
were
offset
higher
selling
expenses
due
to
the
expansion
of
the
sales
force. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
9,425;
after
tax
earnings
were
1,008. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Ronan O'Caoimh, 43 | Chairman
and CEO | Brendan Farrell, 52 | Pres | Jonathan O'Connell, 34 | CFO,
Sec. | James Walsh, Ph.D., 41 | COO |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|